Kybella is an FDA-approved drug owned by Kythera Biopharms. The Active ingredient in Kybella is deoxycholic acid. It was authorized for market use on 29 April, 2015 and is available in solution;subcutaneous dosage forms. The drug holds a total of 15 patents, with none being expired as of now.
The generic versions of Kybella are expected to be released after 02 March, 2030. This is due to its patent US8653058 titled 'Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits', expiring on 2030-03-02 along with other patents like US8101593, US10500214 and US8367649 all having similar expiry dates, blocking the generic entry till then.
Kybella is effectively used as a method for reduction of submental fat, offering improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. deoxycholic acid, its active ingredient contributes to its effectiveness by reducing submental fat volume as described in the approved labeling.
Kybella holds a total of 15 patents with none expired till now. The last patent affecting the Kybella generic release date is expiring on 02 March, 2030. Below is the details of the patent: